Skip to content

Dispensing Study to Assess the Visual Performance of Optimised Prototype Contact Lenses

Dispensing Study to Assess the Visual Performance of Optimised Prototype Contact Lenses

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02484586
Enrollment
161
Registered
2015-06-29
Start date
2015-10-31
Completion date
2017-02-07
Last updated
2017-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Presbyopia, Refractive Error

Keywords

Presbyopia, Refractive error, Contact lens

Brief summary

The aim of this study is to assess the visual performance of multiple optimised prototype soft contact lens designs compared to commercially available contact lenses.

Detailed description

Prospective, double-masked, crossover, bilateral wear, dispensing clinical trial where participants will wear multiple prototype (test) and commercial (control) lenses. Multiple prototype contact lens designs will be assessed against commercial control lenses during the study, where each design will be worn for up to a week. There will be a minimum 1 night washout period between lens designs.

Interventions

DEVICEEtafilcon A

Prototype lens material

Control lens for presbyope group

Control lens for presbyope group

Control lens for presbyope group

DEVICE58% Poly-HEMA

Control lens for presbyope group

Control lens for non-presbyope group

Sponsors

Brien Holden Vision
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Able to read and comprehend English and give informed consent as demonstrated by signing a record of informed consent. * Be at least 18 years old, male or female. * Willing to comply with the wearing and clinical trial visit schedule as directed by the Investigator. * Have ocular health findings considered to be normal and which would not prevent the participant from safely wearing contact lenses. * Is correctable to at least 6/12 (20/40) or better in each eye with contact lenses. * Be suitable and willing to wear contact lenses.

Exclusion criteria

* Any pre-existing ocular irritation, injury or condition (including infection or disease) of the cornea, conjunctiva or eyelids that would preclude contact lens fitting and safe wearing of contact lenses. * Any systemic disease that adversely affects ocular health e.g. diabetes, Graves disease, and auto immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjogrens syndrome and systemic lupus erythematosus. Conditions such as systemic hypertension and arthritis do not automatically exclude prospective participants. * Use of or a need for concurrent category S3 and above ocular medication at enrolment. Ocular medication can be prescribed during the course of the trial as per standard optometric practice. * Use of or a need for any systemic medication or topical medications which may alter normal ocular findings / are known to affect a participant's ocular health / physiology or contact lens performance either in an adverse or beneficial manner at enrolment and/or during the clinical trial. Note: Systemic antihistamines are allowed on an as needed basis, provided they are not used prophylactically during the trial and at least 24 hours before the clinical trial product is used. * Eye surgery within 12 weeks immediately prior to enrolment for this trial. * Previous corneal refractive surgery. * Contraindications to contact lens wear. * Known allergy or intolerance to ingredients in any of the clinical trial products.

Design outcomes

Primary

MeasureTime frameDescription
Visual acuity on a LogMAR (logarithm of the minimum angle of resolution) scaleApproximately 1 week after lens fittingFor each lens, visual acuity will be measured at distance with a computerised LogMAR chart and at near with a near LogMAR chart. Data will be summarised as means +/- standard deviations. No transformation is likely to be required. Visual acuity will be compared between each lens design and control lens types. The significance of lens design will be determined for each visit. Repeated effects linear mixed model with subject random intercepts or paired t tests will be employed for the analysis of visual acuity. Analysis will be performed within each study arm namely presbyopes and non-presbyopes.

Secondary

MeasureTime frameDescription
Subjective rating of vision on a 1-10 visual analogue scaleApproximately 1 week after lens fittingFor each lens, subjective ratings of vision will be assessed with a questionnaire based on a 1 to 10 scale in steps of 1. The questionnaire has been designed specifically for this study. Data will be summarised as means +/- standard deviations. No transformation is likely to be required. Subjective ratings will be compared between each lens design and control lens types. The significance of lens design will be determined for each visit. Repeated effects linear mixed model with subject random intercepts or paired t tests will be employed for the analysis of subjective ratings. Analysis will be performed within each study arm namely presbyopes and non-presbyopes.

Countries

Australia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026